3 cancer drugs from AstraZeneca set to enter late-stage trials

05/17/2013 | Bloomberg Businessweek

AstraZeneca plans to advance its three cancer drug candidates into Phase III trials. Set to advance are moxetumomab pasudotox for patients with hairy cell leukemia, selumetinib for patients with KRAS-positive nonsmall-cell lung cancer, and olaparib for patients with platinum-sensitive relapsed ovarian cancer. The firm also plans to double the number of drugs in its late-stage pipeline and submit three regulatory applications by 2016.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA